Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials

Objectives Combination treatment with erlotinib plus bevacizumab has the potential to become a standard treatment regimen for patients with epidermal growth factor receptor mutation-positive (EGFRm+) advanced non-small cell lung cancer (NSCLC). This study aimed to investigate the efficacy and safety...

Full description

Bibliographic Details

Published in:	BMJ Open
Main Authors:	Ke Wang, Yun Jiang, Jing Luo, Bing Huang, Jinliang Kong, Wusheng Deng, Dingbin Li, Chongxi Bao, Liuyuan Liu
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-08-01
Online Access:	https://bmjopen.bmj.com/content/12/8/e062036.full